Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Market Domination Overtime Host Josh Lipton tracks several of the day's top trending stock tickers, including Adobe's stock ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

Dr Melanie Ivarsson was on Monday named chief executive of the Health Data Research Service (HDRS), which will give ...

US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...